MeiraGTx and ZipBio sign exclusive license agreement for geographic atrophy

MeiraGTx (MGTX) signed an exclusive license agreement with ZipBio, a biotechnology company pioneering AI-driven protein therapeutics. Under the agreement, MeiraGTx will receive exclusive rights to ZipBio’s first-in-class therapies for Geographic Atrophy, targeting the complement pathway. The licensing deal combines MeiraGTx’s vector design, clinical development, and in-house manufacturing of genetic medicines, and ZipBio’s de novo-designed protein therapeutics, developed using its COMPACT generative AI platform. The agreement includes upfront, as well as potential milestone and royalty payments. Financial terms were not disclosed. COMPACT is ZipBio’s proprietary generative AI platform for designing protein therapeutics beyond the limits of conventional biologics.